首页 > 最新文献

Journal of geriatric oncology最新文献

英文 中文
Australian healthcare professionals' experiences and perception of management of older adults with cancer: A qualitative study
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-27 DOI: 10.1016/j.jgo.2025.102234
Sharon He , Heather L. Shepherd , Meera Agar , Rebekah Laidsaar-Powell , Joanne Shaw

Introduction

Older adults with cancer make up a large proportion of cancer diagnoses in Australia. Multimorbidity and aging-related vulnerabilities can make cancer treatment and management challenging. There are limited qualitative studies exploring current practice of care and use of geriatric assessments (GAs) in Australia. This study aimed to qualitatively explore Australian healthcare professionals' (HCPs) experiences of treatment decision-making in relation to older adults with cancer and perceptions of the role of GAs in cancer care in Australia to identify potential barriers to implementation.

Materials and Methods

Australian HCPs providing care for older adults with cancer completed a short online survey and participated in a semi-structured telephone interview exploring their perceptions and experiences of treatment decision-making, and management of older adults with cancer. Purposive sampling ensured representation across disciplines. Thematic analysis using a framework approach identified key themes.

Results

Thirty-one HCPs (n = 19 medical HCPs, n = 7 cancer nurses, n = 5 allied HCPs) completed the online questionnaire. Most participants rated assessment of geriatric domains to be important/very important when considering treatment decisions, however there was variability in perceived importance for assessing objective measures of function and mobility. Of the 31 participants that completed the questionnaire, 29 participated in a semi-structured telephone interview. Qualitative analysis of interviews revealed four main themes: (1) Who do we consider older? Chronological vs. functional age, (2) Clinical management of older adults – theory vs. practice, (3) Is there value in geriatric assessments? (4) Factors that impact GA implementation, and one overarching theme (5) Treatment decision-making for older adults with cancer.

Discussion

This study provides insight into current practice of care for older adults with cancer and the barriers and facilitators to GA implementation within Australian cancer services. Health economic research demonstrating cost-effectiveness of GAs to facilitate system-level change is required. There is also need for further education and training for Australian HCPs on geriatric principles and assessments to improve management for older adults with cancer.
{"title":"Australian healthcare professionals' experiences and perception of management of older adults with cancer: A qualitative study","authors":"Sharon He ,&nbsp;Heather L. Shepherd ,&nbsp;Meera Agar ,&nbsp;Rebekah Laidsaar-Powell ,&nbsp;Joanne Shaw","doi":"10.1016/j.jgo.2025.102234","DOIUrl":"10.1016/j.jgo.2025.102234","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults with cancer make up a large proportion of cancer diagnoses in Australia. Multimorbidity and aging-related vulnerabilities can make cancer treatment and management challenging. There are limited qualitative studies exploring current practice of care and use of geriatric assessments (GAs) in Australia. This study aimed to qualitatively explore Australian healthcare professionals' (HCPs) experiences of treatment decision-making in relation to older adults with cancer and perceptions of the role of GAs in cancer care in Australia to identify potential barriers to implementation.</div></div><div><h3>Materials and Methods</h3><div>Australian HCPs providing care for older adults with cancer completed a short online survey and participated in a semi-structured telephone interview exploring their perceptions and experiences of treatment decision-making, and management of older adults with cancer. Purposive sampling ensured representation across disciplines. Thematic analysis using a framework approach identified key themes.</div></div><div><h3>Results</h3><div>Thirty-one HCPs (<em>n</em> = 19 medical HCPs, <em>n</em> = 7 cancer nurses, <em>n</em> = 5 allied HCPs) completed the online questionnaire. Most participants rated assessment of geriatric domains to be important/very important when considering treatment decisions, however there was variability in perceived importance for assessing objective measures of function and mobility. Of the 31 participants that completed the questionnaire, 29 participated in a semi-structured telephone interview. Qualitative analysis of interviews revealed four main themes: (1) Who do we consider older? Chronological vs. functional age, (2) Clinical management of older adults – theory vs. practice, (3) Is there value in geriatric assessments? (4) Factors that impact GA implementation, and one overarching theme (5) Treatment decision-making for older adults with cancer.</div></div><div><h3>Discussion</h3><div>This study provides insight into current practice of care for older adults with cancer and the barriers and facilitators to GA implementation within Australian cancer services. Health economic research demonstrating cost-effectiveness of GAs to facilitate system-level change is required. There is also need for further education and training for Australian HCPs on geriatric principles and assessments to improve management for older adults with cancer.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 4","pages":"Article 102234"},"PeriodicalIF":3.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preferences for quality of life versus length of life in older women deciding about treatment for early breast cancer: A cross-sectional sub-analysis of the Bridging the Age Gap study 老年妇女在决定早期乳腺癌治疗时对生活质量和生命长度的偏好:缩小年龄差距研究的横断面子分析
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-25 DOI: 10.1016/j.jgo.2025.102226
Jenna L. Morgan , Anne Shrestha , Charlene Martin , Stephen Walters , Michael Bradburn , Malcolm Reed , Thompson G. Robinson , Kwok-Leung Cheung , Riccardo Audisio , Jacqui Gath , Deirdre Revell , Tracy Green , Alistair Ring , Kate J. Lifford , Katherine Brain , Adrian Edwards , Lynda Wyld

Introduction

Prioritising quality of life (QoL) or length of life is often necessary in the decision-making process for cancer care. This may be complicated in patients with limited life expectancy due to age and comorbidities. Older women with early breast cancer often receive non-standard care (primary endocrine therapy [PET] or omission of chemotherapy or radiotherapy) to reduce treatment morbidity and maintain QoL. We aimed to determine the perceived relative influence of QoL versus length of life in treatment decision making by older women with early (potentially curable) breast cancer.

Materials and Methods

This was a sub-study of the Age Gap multi-centre, cohort study, which prospectively recruited women >70 yrs. with early breast cancer. Baseline demographics, health characteristics, and QoL scores were analysed alongside a bespoke questionnaire to assess QoL and length of life preferences, including a modified version of the validated quality/quantity questionnaire, in a subset of the main study.

Results

The questionnaire was sent to 308 patients and 194 (63 %) were returned by participants with a median age of 75 years (range 70–93). Of these, 14 had PET and 180 had standard treatment (ST) (surgery +/− adjuvant therapy) including 37 who had chemotherapy. The PET group was older (median age 83.5 versus 76 years) and in poorer health (9/14; 64.3 % patients had one or more comorbidities versus 69/144; 47.9 %) with inferior baseline physical domain QoL scores. Patients who received PET valued QoL and length of life equally (Q score 0.87, L score 0.91), and patients who received chemotherapy favoured length of life over QoL (Q score 0.67, L score 0.86). Subgroup analysis showed a small correlation between increasing age and QoL preferences (Spearman's r = 0.2, P < 0.009). There was no correlation between co-morbidities, frailty, or global QoL and length of life/QoL preferences.

Discussion

Older women with early breast cancer valued length of life and QoL highly, with an association between preference for QoL and less aggressive treatment choices. Relative QoL preference increased with advancing age. More research is needed to define QoL determinants and outcomes following treatment to help patients make decisions that reflect their priorities.

Trial Registration Number

ISRCTN: 46099296.
{"title":"Preferences for quality of life versus length of life in older women deciding about treatment for early breast cancer: A cross-sectional sub-analysis of the Bridging the Age Gap study","authors":"Jenna L. Morgan ,&nbsp;Anne Shrestha ,&nbsp;Charlene Martin ,&nbsp;Stephen Walters ,&nbsp;Michael Bradburn ,&nbsp;Malcolm Reed ,&nbsp;Thompson G. Robinson ,&nbsp;Kwok-Leung Cheung ,&nbsp;Riccardo Audisio ,&nbsp;Jacqui Gath ,&nbsp;Deirdre Revell ,&nbsp;Tracy Green ,&nbsp;Alistair Ring ,&nbsp;Kate J. Lifford ,&nbsp;Katherine Brain ,&nbsp;Adrian Edwards ,&nbsp;Lynda Wyld","doi":"10.1016/j.jgo.2025.102226","DOIUrl":"10.1016/j.jgo.2025.102226","url":null,"abstract":"<div><h3>Introduction</h3><div>Prioritising quality of life (QoL) or length of life is often necessary in the decision-making process for cancer care. This may be complicated in patients with limited life expectancy due to age and comorbidities. Older women with early breast cancer often receive non-standard care (primary endocrine therapy [PET] or omission of chemotherapy or radiotherapy) to reduce treatment morbidity and maintain QoL. We aimed to determine the perceived relative influence of QoL versus length of life in treatment decision making by older women with early (potentially curable) breast cancer.</div></div><div><h3>Materials and Methods</h3><div>This was a sub-study of the Age Gap multi-centre, cohort study, which prospectively recruited women &gt;70 yrs. with early breast cancer. Baseline demographics, health characteristics, and QoL scores were analysed alongside a bespoke questionnaire to assess QoL and length of life preferences, including a modified version of the validated quality/quantity questionnaire, in a subset of the main study.</div></div><div><h3>Results</h3><div>The questionnaire was sent to 308 patients and 194 (63 %) were returned by participants with a median age of 75 years (range 70–93). Of these, 14 had PET and 180 had standard treatment (ST) (surgery +/− adjuvant therapy) including 37 who had chemotherapy. The PET group was older (median age 83.5 versus 76 years) and in poorer health (9/14; 64.3 % patients had one or more comorbidities versus 69/144; 47.9 %) with inferior baseline physical domain QoL scores. Patients who received PET valued QoL and length of life equally (Q score 0.87, L score 0.91), and patients who received chemotherapy favoured length of life over QoL (Q score 0.67, L score 0.86). Subgroup analysis showed a small correlation between increasing age and QoL preferences (Spearman's <em>r</em> = 0.2, <em>P</em> &lt; 0.009). There was no correlation between co-morbidities, frailty, or global QoL and length of life/QoL preferences.</div></div><div><h3>Discussion</h3><div>Older women with early breast cancer valued length of life and QoL highly, with an association between preference for QoL and less aggressive treatment choices. Relative QoL preference increased with advancing age. More research is needed to define QoL determinants and outcomes following treatment to help patients make decisions that reflect their priorities.</div></div><div><h3>Trial Registration Number</h3><div>ISRCTN: 46099296.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 4","pages":"Article 102226"},"PeriodicalIF":3.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What are the determinants of functional decline in older adults with cancer? Results from the INCAPAC study
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-22 DOI: 10.1016/j.jgo.2025.102223
Yvanna Simon , Catherine Helmer , Fleur Delva , Isabelle Baldi , Gaëlle Coureau , Sandra Leguyader-Peyrou , Hélène Amieva , Simone Mathoulin-Pelissier , Karine Pérès , Angéline Galvin

Introduction

Older adults with cancer are exposed to greater difficulties in carrying out their daily activities due to cancer itself, its treatment, or both. The aim of this study was to describe functional decline after cancer diagnosis and to investigate the determinants of this decline among older individuals with cancer.

Materials and Methods

Using the Gironde cancer registries, older subjects (≥65 years) with a diagnosis of cancer between 2005 and 2018 were identified in three prospective cohorts on aging. Functional decline was defined as an increase of 1 point for Activities of Daily Living (ADL), 2 points for Instrumental Activities of Daily Living (IADL), and 3 points for the overall score (ADL + IADL) between cancer pre- and post-diagnosis visits. Logistic regression models were used to identify determinants of functional decline among older subjects who underwent a post-diagnostic assessment. Additionally, multinomial logistic regression models were performed to account for individuals who had died prior to the post-diagnostic cancer visit.

Results

A total of 306 individuals followed-up after the cancer diagnosis were included (median age at cancer diagnosis: 83; 44 % female). Older age at cancer, low educational level, impaired initial functional status, and poor five-year cancer-related prognosis were significantly associated with functional decline across all three scores. Multinomial logistic regression analyses (n = 489) yielded similar results, but only cancer-related factors, specifically unfavorable vital prognosis, were associated with higher risk of death.

Discussion

Functional decline in older individuals with cancer is both multifactorial and multidimensional. Further studies are needed to disentangle the effects of cancer and aging.
导言:由于癌症本身、癌症治疗或两者兼而有之,患有癌症的老年人在进行日常活动时面临着更大的困难。本研究旨在描述癌症确诊后功能衰退的情况,并调查癌症老年患者功能衰退的决定因素。材料与方法利用吉伦特省癌症登记处,在三个老龄化前瞻性队列中确定了 2005 年至 2018 年期间确诊癌症的老年受试者(≥65 岁)。功能衰退的定义是:在癌症确诊前和确诊后两次就诊之间,日常生活活动(ADL)增加 1 分,工具性日常生活活动(IADL)增加 2 分,总分(ADL + IADL)增加 3 分。逻辑回归模型用于确定接受诊断后评估的老年受试者功能下降的决定因素。结果 共纳入 306 名癌症诊断后随访者(癌症诊断时的中位年龄:83 岁;44% 为女性)。在所有三项评分中,患癌年龄较大、教育程度较低、初始功能状态受损以及五年内癌症相关预后较差与功能衰退有显著相关性。多项式逻辑回归分析(n = 489)也得出了类似的结果,但只有癌症相关因素,特别是不利的重要预后,才与较高的死亡风险相关。需要进一步的研究来区分癌症和衰老的影响。
{"title":"What are the determinants of functional decline in older adults with cancer? Results from the INCAPAC study","authors":"Yvanna Simon ,&nbsp;Catherine Helmer ,&nbsp;Fleur Delva ,&nbsp;Isabelle Baldi ,&nbsp;Gaëlle Coureau ,&nbsp;Sandra Leguyader-Peyrou ,&nbsp;Hélène Amieva ,&nbsp;Simone Mathoulin-Pelissier ,&nbsp;Karine Pérès ,&nbsp;Angéline Galvin","doi":"10.1016/j.jgo.2025.102223","DOIUrl":"10.1016/j.jgo.2025.102223","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults with cancer are exposed to greater difficulties in carrying out their daily activities due to cancer itself, its treatment, or both. The aim of this study was to describe functional decline after cancer diagnosis and to investigate the determinants of this decline among older individuals with cancer.</div></div><div><h3>Materials and Methods</h3><div>Using the Gironde cancer registries, older subjects (≥65 years) with a diagnosis of cancer between 2005 and 2018 were identified in three prospective cohorts on aging. Functional decline was defined as an increase of 1 point for Activities of Daily Living (ADL), 2 points for Instrumental Activities of Daily Living (IADL), and 3 points for the overall score (ADL + IADL) between cancer pre- and post-diagnosis visits. Logistic regression models were used to identify determinants of functional decline among older subjects who underwent a post-diagnostic assessment. Additionally, multinomial logistic regression models were performed to account for individuals who had died prior to the post-diagnostic cancer visit.</div></div><div><h3>Results</h3><div>A total of 306 individuals followed-up after the cancer diagnosis were included (median age at cancer diagnosis: 83; 44 % female). Older age at cancer, low educational level, impaired initial functional status, and poor five-year cancer-related prognosis were significantly associated with functional decline across all three scores. Multinomial logistic regression analyses (<em>n</em> = 489) yielded similar results, but only cancer-related factors, specifically unfavorable vital prognosis, were associated with higher risk of death.</div></div><div><h3>Discussion</h3><div>Functional decline in older individuals with cancer is both multifactorial and multidimensional. Further studies are needed to disentangle the effects of cancer and aging.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 4","pages":"Article 102223"},"PeriodicalIF":3.0,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of electronic patient-reported outcomes presentation during multi-disciplinary tumor board on clinician discussion of older adults' fitness and preferences
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-21 DOI: 10.1016/j.jgo.2025.102225
Nicole L. Henderson , Garrett Bourne , Etzael Ortiz-Olguin , Cameron Pywell , J. Bart Rose , Grant R. Williams , S.M. Qasim Hussaini , Ryan D. Nipp , Gabrielle Rocque

Introduction

Treatment of pancreatic cancer often entails multiple modalities (e.g., chemotherapy, surgery, radiation) that vary in intensity, timing, and toxicity profiles. Some treatment options are only recommended for medically ‘fit’ patients regardless of age, yet formal fitness measures (such as the geriatric assessment [GA]) and patient preferences are seldom utilized during treatment decision-making.

Materials and Methods

The INtegrating Systematic PatIent-Reported Evaluations into Multi-Disciplinary Tumor Board (INSPIRE-MDTB) intervention involves the presentation of GA and treatment preferences data during tumor board discussions of older patients with stage I-IV pancreatic adenocarcinoma. This qualitative study recorded, transcribed, and inductively analyzed historical (November 2021–February 2022) and intervention (September 2022–June 2023) MDTBs using NVivo software. A constant comparative method was used to establish a grounded scheme representative of clinicians' characterization of patients' fitness and preferences during decision-making.

Results

Recordings of the primary MDTB presentation of 31 historical and 49 intervention patients with similar sex (52 %; 53 % female), age (m = 68.1; 72.3), race (65 %; 59 % White), and cancer stage (26 %; 22 % stage IV) were included. Although GA was captured for all included patients, it was not discussed in any historical cases, but was in 94 % of intervention cases. When compared to historical controls, INSPIRE patients had more frequent discussions of (1) cancer-related factors (e.g., size, location, rate of progression; 35 % vs. 43 %), (2) individual risk factors (e.g., age, comorbidities, tolerance; 90 % vs 98 %), and (3) psychosocial factors (e.g., health literacy, social support, substance use; 19 % vs 33 %). Identified preference domains were discussed in 39 % of historical and 80 % of intervention patients, with notably higher rates of discussion of patients' concerns regarding physical (0 %; 35 %) and mental/emotional (0 %; 20 %) side effects, ability to work (0 %; 10 %), and the logistics and convenience of treatment (6 %; 14 %).

Discussion

The INSPIRE intervention enhanced MDTB discussion of patient fitness and preferences and represents a promising approach for fostering consistent and systematic presentation and discussion of patient-reported data, such as the GA and treatment preferences. This adds to our previous findings that INSPIRE was feasible, acceptable, appropriate, and time-effective according to patients and provider participants.
{"title":"The impact of electronic patient-reported outcomes presentation during multi-disciplinary tumor board on clinician discussion of older adults' fitness and preferences","authors":"Nicole L. Henderson ,&nbsp;Garrett Bourne ,&nbsp;Etzael Ortiz-Olguin ,&nbsp;Cameron Pywell ,&nbsp;J. Bart Rose ,&nbsp;Grant R. Williams ,&nbsp;S.M. Qasim Hussaini ,&nbsp;Ryan D. Nipp ,&nbsp;Gabrielle Rocque","doi":"10.1016/j.jgo.2025.102225","DOIUrl":"10.1016/j.jgo.2025.102225","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatment of pancreatic cancer often entails multiple modalities (e.g., chemotherapy, surgery, radiation) that vary in intensity, timing, and toxicity profiles. Some treatment options are only recommended for medically ‘fit’ patients regardless of age, yet formal fitness measures (such as the geriatric assessment [GA]) and patient preferences are seldom utilized during treatment decision-making.</div></div><div><h3>Materials and Methods</h3><div>The INtegrating Systematic PatIent-Reported Evaluations into Multi-Disciplinary Tumor Board (INSPIRE-MDTB) intervention involves the presentation of GA and treatment preferences data during tumor board discussions of older patients with stage I-IV pancreatic adenocarcinoma. This qualitative study recorded, transcribed, and inductively analyzed historical (November 2021–February 2022) and intervention (September 2022–June 2023) MDTBs using NVivo software. A constant comparative method was used to establish a grounded scheme representative of clinicians' characterization of patients' fitness and preferences during decision-making.</div></div><div><h3>Results</h3><div>Recordings of the primary MDTB presentation of 31 historical and 49 intervention patients with similar sex (52 %; 53 % female), age (m = 68.1; 72.3), race (65 %; 59 % White), and cancer stage (26 %; 22 % stage IV) were included. Although GA was captured for all included patients, it was not discussed in any historical cases, but was in 94 % of intervention cases. When compared to historical controls, INSPIRE patients had more frequent discussions of (1) cancer-related factors (e.g., size, location, rate of progression; 35 % vs. 43 %), (2) individual risk factors (e.g., age, comorbidities, tolerance; 90 % vs 98 %), and (3) psychosocial factors (e.g., health literacy, social support, substance use; 19 % vs 33 %). Identified preference domains were discussed in 39 % of historical and 80 % of intervention patients, with notably higher rates of discussion of patients' concerns regarding physical (0 %; 35 %) and mental/emotional (0 %; 20 %) side effects, ability to work (0 %; 10 %), and the logistics and convenience of treatment (6 %; 14 %).</div></div><div><h3>Discussion</h3><div>The INSPIRE intervention enhanced MDTB discussion of patient fitness and preferences and represents a promising approach for fostering consistent and systematic presentation and discussion of patient-reported data, such as the GA and treatment preferences. This adds to our previous findings that INSPIRE was feasible, acceptable, appropriate, and time-effective according to patients and provider participants.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 4","pages":"Article 102225"},"PeriodicalIF":3.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Distress Thermometer in older patients with cancer
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-21 DOI: 10.1016/j.jgo.2025.102221
Charlotte Zuber , Kristine Swartz , Andrew E. Chapman , Lora Rhodes , Ting Ting Zhan , Kuang-Yi Wen

Introduction

The Geriatric Depression Scale is a useful tool in screening for depression in older adults, a particularly vulnerable population in oncology. The National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) has been validated as a fast and effective screening tool for psychological distress in general oncology populations, and it could possibly be used as a surrogate for the longer Geriatric Depression Scale (GDS) test in older adults with cancer.

Materials and Methods

In this retrospective cross-sectional study in older adults prior to starting cancer treatment, we evaluated the relationship between the DT and GDS by comparing 242 older adults with cancers' DT scores to their GDS scores, used receiver operating characteristic analysis to determine a DT cutoff score, and used logistic regression to identify variables associated with higher distress.

Results

The Spearman correlation coefficient between GDS and DT was 0.41, p < 0.001. A cutoff score of 4 was found to be most sensitive and specific (0.66,0.68) for predicting a positive GDS (c-index = 0.70).

Discussion

These results indicate the potential utility of the DT as a mildly to moderately effective screening tool for depression in older adults with cancer starting treatment and support the current NCCN cutoff guidelines to indicate the need for additional distress interventions.
{"title":"Evaluation of the Distress Thermometer in older patients with cancer","authors":"Charlotte Zuber ,&nbsp;Kristine Swartz ,&nbsp;Andrew E. Chapman ,&nbsp;Lora Rhodes ,&nbsp;Ting Ting Zhan ,&nbsp;Kuang-Yi Wen","doi":"10.1016/j.jgo.2025.102221","DOIUrl":"10.1016/j.jgo.2025.102221","url":null,"abstract":"<div><h3>Introduction</h3><div>The Geriatric Depression Scale is a useful tool in screening for depression in older adults, a particularly vulnerable population in oncology. The National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) has been validated as a fast and effective screening tool for psychological distress in general oncology populations, and it could possibly be used as a surrogate for the longer Geriatric Depression Scale (GDS) test in older adults with cancer.</div></div><div><h3>Materials and Methods</h3><div>In this retrospective cross-sectional study in older adults prior to starting cancer treatment, we evaluated the relationship between the DT and GDS by comparing 242 older adults with cancers' DT scores to their GDS scores, used receiver operating characteristic analysis to determine a DT cutoff score, and used logistic regression to identify variables associated with higher distress.</div></div><div><h3>Results</h3><div>The Spearman correlation coefficient between GDS and DT was 0.41, <em>p</em> &lt; 0.001. A cutoff score of 4 was found to be most sensitive and specific (0.66,0.68) for predicting a positive GDS (c-index = 0.70).</div></div><div><h3>Discussion</h3><div>These results indicate the potential utility of the DT as a mildly to moderately effective screening tool for depression in older adults with cancer starting treatment and support the current NCCN cutoff guidelines to indicate the need for additional distress interventions.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 4","pages":"Article 102221"},"PeriodicalIF":3.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspectives on prehabilitation for older adults with cancer: A report from the International Society of Geriatric Oncology (SIOG) rehabilitation group 老年癌症患者康复前的观点:国际老年肿瘤学会(SIOG)康复小组的报告
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-16 DOI: 10.1016/j.jgo.2025.102224
Efthymios Papadopoulos , Rachelle Brick , Ailsa Sirois , Bérengére Beauplet , Kelley C. Wood , Hannah Furness , Caitriona Barrett , Aida Ward , Jane Murphy , Megan Pattwell , Erna Carmen Navarrete , Kate Williams , Kristen Haase
{"title":"Perspectives on prehabilitation for older adults with cancer: A report from the International Society of Geriatric Oncology (SIOG) rehabilitation group","authors":"Efthymios Papadopoulos ,&nbsp;Rachelle Brick ,&nbsp;Ailsa Sirois ,&nbsp;Bérengére Beauplet ,&nbsp;Kelley C. Wood ,&nbsp;Hannah Furness ,&nbsp;Caitriona Barrett ,&nbsp;Aida Ward ,&nbsp;Jane Murphy ,&nbsp;Megan Pattwell ,&nbsp;Erna Carmen Navarrete ,&nbsp;Kate Williams ,&nbsp;Kristen Haase","doi":"10.1016/j.jgo.2025.102224","DOIUrl":"10.1016/j.jgo.2025.102224","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102224"},"PeriodicalIF":3.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unsupervised learning to identify symptom clusters in older adults undergoing chemotherapy
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-14 DOI: 10.1016/j.jgo.2025.102222
Erika Ramsdale , Yilin Zhou , Lisa Smith , Huiwen Xu , Rachael Tylock , Marie Flannery , Supriya Mohile , Ajay Anand

Introduction

Unsupervised machine learning (ML) approaches such as clustering have not been commonly applied to patient-reported data. This study describes ML methods to explore and describe patient-reported symptom trajectories in older adults receiving chemotherapy.

Materials and Methods

This secondary analysis of prospectively collected data from the GAP 70+ Trial (NCT02054741; PI: Mohile) collected patient-reported symptoms at baseline (pre-chemotherapy), six weeks, three months, and six months. Complete patient-reported symptom data were available for at least one timepoint for 708/718 patients (98.6 %). Correlation analysis was performed on all symptom items. Multiple clustering algorithms were applied to selected baseline symptoms as an exploratory analysis, using gap statistic and elbow plots to understand optimal cluster numbers for each algorithm. Silhouette scores and t-stochastic neighbor embedding (t-SNE) plots were generated for each algorithm. Hierarchical agglomerative clustering was applied to symptoms at each timepoint, and clusters generated for each timepoint were examined longitudinally utilizing statistical measures, violin plots, and a Sankey diagram.

Results

Twenty-six patient-reported items were used for clustering analyses, representing symptom severity and interference. There was significant variability in how different unsupervised learning algorithms clustered the baseline symptom data. Silhouette scores ranged from −0.22 (OPTICS) to 0.16 (BIRCH). Examining agglomerative clustering across timepoints, cluster composition was largely driven by the symptom sum score (i.e., adding the Likert-scale scores). Most patients had “low” symptoms at baseline that remained low, but symptom trajectory was otherwise heterogeneous. A small number of patients had high hand-foot/neuropathy symptoms (but low other symptoms) at six weeks, and another small cluster had high mucosal toxicity at six months. Despite specific symptom patterns in these small clusters, chemotherapy regimens varied.

Discussion

Unsupervised machine learning techniques may be helpful to understand longitudinal patient-reported data such as symptoms. They permit data-driven exploration, which may uncover patterns to inform hypotheses or further analysis (e.g., outcome prediction). Results of clustering analyses should be validated through further hypothesis-driven analysis. In this analysis, it was challenging to uncover consistent symptom patterns, though it suggests symptom composite (sum) scores may warrant further investigation. Clinicians should understand the philosophy, strengths, and limitations of an unsupervised machine learning approach applied to patient data.
导言聚类等无监督机器学习(ML)方法尚未普遍应用于患者报告的数据。本研究介绍了探索和描述接受化疗的老年人患者报告症状轨迹的 ML 方法。材料与方法本研究对 GAP 70+ 试验(NCT02054741;PI:Mohile)收集的前瞻性数据进行了二次分析,收集了患者在基线(化疗前)、六周、三个月和六个月时报告的症状。708/718名患者(98.6%)至少有一个时间点的完整患者症状报告数据。对所有症状项目进行了相关性分析。对选定的基线症状采用多种聚类算法进行探索性分析,利用差距统计和肘图了解每种算法的最佳聚类数。每种算法都生成了剪影评分和 t-随机邻接嵌入(t-SNE)图。对每个时间点的症状进行分层聚类,并利用统计量、小提琴图和桑基图对每个时间点生成的聚类进行纵向检查。结果聚类分析使用了 26 个患者报告的项目,代表症状严重程度和干扰。不同的无监督学习算法对基线症状数据进行聚类的方式存在很大差异。剪影得分从-0.22(OPTICS)到0.16(BIRCH)不等。在对各时间点进行聚类时,聚类组成主要由症状总分(即李克特量表得分的总和)驱动。大多数患者在基线时症状 "较轻",且持续较轻,但症状轨迹在其他方面存在差异。少数患者在六周时手足/神经病变症状较重(但其他症状较轻),另一小部分患者在六个月时粘膜毒性较重。讨论无监督机器学习技术可能有助于理解纵向患者报告数据(如症状)。无监督机器学习技术有助于理解患者纵向报告的数据(如症状),它们允许数据驱动的探索,从而发现模式,为假设或进一步分析(如结果预测)提供依据。聚类分析的结果应通过进一步的假设驱动分析来验证。在这项分析中,发现一致的症状模式具有挑战性,不过这表明症状综合(总和)评分可能值得进一步研究。临床医生应该了解应用于患者数据的无监督机器学习方法的理念、优势和局限性。
{"title":"Unsupervised learning to identify symptom clusters in older adults undergoing chemotherapy","authors":"Erika Ramsdale ,&nbsp;Yilin Zhou ,&nbsp;Lisa Smith ,&nbsp;Huiwen Xu ,&nbsp;Rachael Tylock ,&nbsp;Marie Flannery ,&nbsp;Supriya Mohile ,&nbsp;Ajay Anand","doi":"10.1016/j.jgo.2025.102222","DOIUrl":"10.1016/j.jgo.2025.102222","url":null,"abstract":"<div><h3>Introduction</h3><div>Unsupervised machine learning (ML) approaches such as clustering have not been commonly applied to patient-reported data. This study describes ML methods to explore and describe patient-reported symptom trajectories in older adults receiving chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>This secondary analysis of prospectively collected data from the GAP 70+ Trial (<span><span>NCT02054741</span><svg><path></path></svg></span>; PI: Mohile) collected patient-reported symptoms at baseline (pre-chemotherapy), six weeks, three months, and six months. Complete patient-reported symptom data were available for at least one timepoint for 708/718 patients (98.6 %). Correlation analysis was performed on all symptom items. Multiple clustering algorithms were applied to selected baseline symptoms as an exploratory analysis, using gap statistic and elbow plots to understand optimal cluster numbers for each algorithm. Silhouette scores and t-stochastic neighbor embedding (t-SNE) plots were generated for each algorithm. Hierarchical agglomerative clustering was applied to symptoms at each timepoint, and clusters generated for each timepoint were examined longitudinally utilizing statistical measures, violin plots, and a Sankey diagram.</div></div><div><h3>Results</h3><div>Twenty-six patient-reported items were used for clustering analyses, representing symptom severity and interference. There was significant variability in how different unsupervised learning algorithms clustered the baseline symptom data. Silhouette scores ranged from −0.22 (OPTICS) to 0.16 (BIRCH). Examining agglomerative clustering across timepoints, cluster composition was largely driven by the symptom sum score (i.e., adding the Likert-scale scores). Most patients had “low” symptoms at baseline that remained low, but symptom trajectory was otherwise heterogeneous. A small number of patients had high hand-foot/neuropathy symptoms (but low other symptoms) at six weeks, and another small cluster had high mucosal toxicity at six months. Despite specific symptom patterns in these small clusters, chemotherapy regimens varied.</div></div><div><h3>Discussion</h3><div>Unsupervised machine learning techniques may be helpful to understand longitudinal patient-reported data such as symptoms. They permit data-driven exploration, which may uncover patterns to inform hypotheses or further analysis (e.g., outcome prediction). Results of clustering analyses should be validated through further hypothesis-driven analysis. In this analysis, it was challenging to uncover consistent symptom patterns, though it suggests symptom composite (sum) scores may warrant further investigation. Clinicians should understand the philosophy, strengths, and limitations of an unsupervised machine learning approach applied to patient data.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102222"},"PeriodicalIF":3.0,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term mortality in older (≥70 years) patients with early breast cancer treated with neo‐/adjuvant chemotherapy: A Swedish nationwide retrospective population-based study
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-13 DOI: 10.1016/j.jgo.2025.102220
Christine Lundgren , Kristina Engvall , Irma Fredriksson , Antonios Valachis

Introduction

There are substantial differences in the utilization of chemotherapy between younger and older patients, mainly due to the higher risk for adverse events among older patients. Short-term mortality after chemotherapy could reveal fatal side effects of treatment. The aim of this study was to explore the impact of treatment setting (neoadjuvant vs. adjuvant) and different chemotherapeutic agents on short-term mortality among older patients with early breast cancer.

Material and Methods

The population-based, national, research database BCBaSe 3.0 was used as a data source to identify older (≥70 years old) patients with stage I–III breast cancer, diagnosed between 2008 and 2019, who received neoadjuvant or adjuvant chemotherapy. Primary outcome was short-term mortality defined as death due to any cause within one year after breast cancer diagnosis. Multivariable logistic regression analysis was applied to investigate the impact of treatment setting and different chemotherapeutic agents (anthracycline-based vs. taxane-based vs. sequential anthracyclines and taxanes) on outcome, adjusted for potential confounders.

Results

In total, 4,072 older patients were treated with neoadjuvant or adjuvant chemotherapy and median age was 73 years (quartile [Q]1–Q3; 71–75). The one-year mortality rate was 1.5 % (95 % confidence interval [CI]: 1.2–1.9 % [63 of 4072 patients]). Risk factors independently associated with one-year mortality were older age, larger tumor size, positive nodal status, presence of triple negative breast cancer, and use of neoadjuvant as compared to adjuvant chemotherapy (odds ratio [OR]: 2.00, 95 % CI: 1.04–3.84). No association was found between type of chemotherapeutic regimen and one-year mortality. Median time to death was 7 months (interquartile range: 5–9). The reason for death was mainly classified as breast cancer-related (neoadjuvant: 78 %, n = 14; adjuvant: 49 %, n = 22), followed by potential treatment-related deaths (neoadjuvant: 11 %, n = 2; adjuvant: 27 %, n = 12).

Discussion

The short-term mortality rate at first year after diagnosis among older (≥70 years) patients with breast cancer was relatively low. The higher risk among patients treated with neoadjuvant chemotherapy could be attributed to residual confounding and deserves further evaluation. The low risk of potential treatment-associated death suggests that chemotherapy in this respect is safe, and older patients should not be disqualified for this treatment.
{"title":"Short-term mortality in older (≥70 years) patients with early breast cancer treated with neo‐/adjuvant chemotherapy: A Swedish nationwide retrospective population-based study","authors":"Christine Lundgren ,&nbsp;Kristina Engvall ,&nbsp;Irma Fredriksson ,&nbsp;Antonios Valachis","doi":"10.1016/j.jgo.2025.102220","DOIUrl":"10.1016/j.jgo.2025.102220","url":null,"abstract":"<div><h3>Introduction</h3><div>There are substantial differences in the utilization of chemotherapy between younger and older patients, mainly due to the higher risk for adverse events among older patients. Short-term mortality after chemotherapy could reveal fatal side effects of treatment. The aim of this study was to explore the impact of treatment setting (neoadjuvant vs. adjuvant) and different chemotherapeutic agents on short-term mortality among older patients with early breast cancer.</div></div><div><h3>Material and Methods</h3><div>The population-based, national, research database BCBaSe 3.0 was used as a data source to identify older (≥70 years old) patients with stage I–III breast cancer, diagnosed between 2008 and 2019, who received neoadjuvant or adjuvant chemotherapy. Primary outcome was short-term mortality defined as death due to any cause within one year after breast cancer diagnosis. Multivariable logistic regression analysis was applied to investigate the impact of treatment setting and different chemotherapeutic agents (anthracycline-based vs. taxane-based vs. sequential anthracyclines and taxanes) on outcome, adjusted for potential confounders.</div></div><div><h3>Results</h3><div>In total, 4,072 older patients were treated with neoadjuvant or adjuvant chemotherapy and median age was 73 years (quartile [Q]1–Q3; 71–75). The one-year mortality rate was 1.5 % (95 % confidence interval [CI]: 1.2–1.9 % [63 of 4072 patients]). Risk factors independently associated with one-year mortality were older age, larger tumor size, positive nodal status, presence of triple negative breast cancer, and use of neoadjuvant as compared to adjuvant chemotherapy (odds ratio [OR]: 2.00, 95 % CI: 1.04–3.84). No association was found between type of chemotherapeutic regimen and one-year mortality. Median time to death was 7 months (interquartile range: 5–9). The reason for death was mainly classified as breast cancer-related (neoadjuvant: 78 %, <em>n</em> = 14; adjuvant: 49 %, <em>n</em> = 22), followed by potential treatment-related deaths (neoadjuvant: 11 %, n = 2; adjuvant: 27 %, <em>n</em> = 12).</div></div><div><h3>Discussion</h3><div>The short-term mortality rate at first year after diagnosis among older (≥70 years) patients with breast cancer was relatively low. The higher risk among patients treated with neoadjuvant chemotherapy could be attributed to residual confounding and deserves further evaluation. The low risk of potential treatment-associated death suggests that chemotherapy in this respect is safe, and older patients should not be disqualified for this treatment.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102220"},"PeriodicalIF":3.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-08 DOI: 10.1016/j.jgo.2025.102219
Enrica Antonia Martino , Ernesto Vigna , Paola De Luca , Antonella Bruzzese , Caterina Labanca , Francesco Mendicino , Eugenio Lucia , Virginia Olivito , Valentina Fragliasso , Antonino Neri , Fortunato Morabito , Andrea Corsonello , Massimo Gentile

Introduction

Chronic lymphocytic leukemia (CLL) particularly impacts older adults with multiple comorbidities. The advent of targeted therapies has improved outcomes, but challenges related to treatment adherence and drug interactions persist. Assessment of frailty is recommended to tailor treatment, though its application in clinical settings is often limited due to its complexity. This study aimed to investigate the predictive value of frailty regarding treatment toxicity and discontinuation in older patients with CLL treated with targeted therapies.

Materials and Methods

This prospective cohort study involved 82 older adults with CLL (≥65 years) treated with Bruton's tyrosine kinase inhibitors (BTKi) or BCL-2 inhibitors (BCL-2i) from November 2018 to February 2024. Patients were assessed by the Canadian Study of Health and Aging (CSHA) Clinical Frailty Scale (CFS) within a week before starting treatment. Demographics, CLL characteristics, comorbidities, and treatment-related adverse events were collected. Statistical analyses included receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off for predicting treatment discontinuation due to toxicity.

Results

The median age of patients was 75 years. Most patients (90.2 %) were at Binet stage B/C, with 14.6 % having 17p deletion and 17.1 % TP53 mutations. Overall, 46 patients experienced treatment-related toxicity. The ROC curve analysis showed that the best cut-off for predicting treatment-related toxicity was a CSHA CFS >3. The accuracy was fair, with an area under the curve (AUC) of 0.695 (95 % CI 0.55–0.84; P = 0.02), sensitivity = 85 % and specificity = 53 %. Patients with a score > 3 experienced higher rates of treatment discontinuation (28.6 %) compared to those with a score ≤ 3 (12.5 %; P < 0.05). Other factors such as polypharmacy, cumulative illness rating, and comorbidity indices did not significantly affect treatment discontinuation rates.

Discussion

The CSHA CFS is a feasible tool for identifying older adults with CLL at higher risk of treatment toxicity and discontinuation. Patients with a CFS >3 had a significantly higher likelihood of treatment interruption due to adverse effects. Therefore, CSHA CFS can aid in stratifying patients and optimizing therapeutic strategies. Further validation in multicenter studies is warranted to confirm these results and explore the potential for adjusting treatment dosages based on frailty assessments in the era of targeted therapies.
{"title":"Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study","authors":"Enrica Antonia Martino ,&nbsp;Ernesto Vigna ,&nbsp;Paola De Luca ,&nbsp;Antonella Bruzzese ,&nbsp;Caterina Labanca ,&nbsp;Francesco Mendicino ,&nbsp;Eugenio Lucia ,&nbsp;Virginia Olivito ,&nbsp;Valentina Fragliasso ,&nbsp;Antonino Neri ,&nbsp;Fortunato Morabito ,&nbsp;Andrea Corsonello ,&nbsp;Massimo Gentile","doi":"10.1016/j.jgo.2025.102219","DOIUrl":"10.1016/j.jgo.2025.102219","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic lymphocytic leukemia (CLL) particularly impacts older adults with multiple comorbidities. The advent of targeted therapies has improved outcomes, but challenges related to treatment adherence and drug interactions persist. Assessment of frailty is recommended to tailor treatment, though its application in clinical settings is often limited due to its complexity. This study aimed to investigate the predictive value of frailty regarding treatment toxicity and discontinuation in older patients with CLL treated with targeted therapies.</div></div><div><h3>Materials and Methods</h3><div>This prospective cohort study involved 82 older adults with CLL (≥65 years) treated with Bruton's tyrosine kinase inhibitors (BTKi) or BCL-2 inhibitors (BCL-2i) from November 2018 to February 2024. Patients were assessed by the Canadian Study of Health and Aging (CSHA) Clinical Frailty Scale (CFS) within a week before starting treatment. Demographics, CLL characteristics, comorbidities, and treatment-related adverse events were collected. Statistical analyses included receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off for predicting treatment discontinuation due to toxicity.</div></div><div><h3>Results</h3><div>The median age of patients was 75 years. Most patients (90.2 %) were at Binet stage B/C, with 14.6 % having 17p deletion and 17.1 % <em>TP53</em> mutations. Overall, 46 patients experienced treatment-related toxicity. The ROC curve analysis showed that the best cut-off for predicting treatment-related toxicity was a CSHA CFS &gt;3. The accuracy was fair, with an area under the curve (AUC) of 0.695 (95 % CI 0.55–0.84; <em>P</em> = 0.02), sensitivity = 85 % and specificity = 53 %. Patients with a score &gt; 3 experienced higher rates of treatment discontinuation (28.6 %) compared to those with a score ≤ 3 (12.5 %; <em>P</em> &lt; 0.05). Other factors such as polypharmacy, cumulative illness rating, and comorbidity indices did not significantly affect treatment discontinuation rates.</div></div><div><h3>Discussion</h3><div>The CSHA CFS is a feasible tool for identifying older adults with CLL at higher risk of treatment toxicity and discontinuation. Patients with a CFS &gt;3 had a significantly higher likelihood of treatment interruption due to adverse effects. Therefore, CSHA CFS can aid in stratifying patients and optimizing therapeutic strategies. Further validation in multicenter studies is warranted to confirm these results and explore the potential for adjusting treatment dosages based on frailty assessments in the era of targeted therapies.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102219"},"PeriodicalIF":3.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of home step-tracking using wearable devices for older adults undergoing thoracic surgery: A brief report
IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Pub Date : 2025-03-04 DOI: 10.1016/j.jgo.2025.102218
Anupama Singh , Mary E. Cooley , Emanuele Mazzola , Ashley L. Deeb , Miles McAllister , Fatemehsadat Pezeshkian , Clark DuMontier , Laura N. Frain , Paula Ugalde Figueroa , Desiree Steimer , Michael T. Jaklitsch
{"title":"Feasibility of home step-tracking using wearable devices for older adults undergoing thoracic surgery: A brief report","authors":"Anupama Singh ,&nbsp;Mary E. Cooley ,&nbsp;Emanuele Mazzola ,&nbsp;Ashley L. Deeb ,&nbsp;Miles McAllister ,&nbsp;Fatemehsadat Pezeshkian ,&nbsp;Clark DuMontier ,&nbsp;Laura N. Frain ,&nbsp;Paula Ugalde Figueroa ,&nbsp;Desiree Steimer ,&nbsp;Michael T. Jaklitsch","doi":"10.1016/j.jgo.2025.102218","DOIUrl":"10.1016/j.jgo.2025.102218","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 3","pages":"Article 102218"},"PeriodicalIF":3.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of geriatric oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1